Pilot study tests imepitoin for cats’ veterinary visit stress

A pilot study in Veterinary Sciences suggests imepitoin may help reduce cats’ stress around veterinary visits, adding an early signal for a drug class more familiar to veterinarians from canine neurology and behavior work. In the randomized, placebo-controlled study, 32 cats were assigned to a single oral dose of imepitoin or placebo before a veterinary visit, then assessed with behavioral and physiologic measures including heart rate and respiratory rate. The paper builds on earlier evidence that imepitoin has anxiolytic effects in dogs and has been reported as generally well tolerated in cats, but this appears to be exploratory feline work rather than a practice-changing result on its own. (pubmed.ncbi.nlm.nih.gov)

Why it matters: Feline visit-related stress remains a practical barrier to care, affecting patient welfare, client compliance, handling safety, and even the reliability of exam findings. That’s why pre-visit pharmaceuticals have drawn so much interest, with gabapentin already widely discussed in the literature and pregabalin oral solution having published field-study data showing reduced transport- and visit-related fear in cats. If imepitoin can eventually show a consistent benefit with acceptable tolerability in larger controlled trials, it could broaden the toolkit for cat-friendly handling, especially for patients that don’t respond well to current options. (mdpi.com)

What to watch: The next step is whether larger, blinded feline studies confirm efficacy, define dosing and timing, and clarify where imepitoin would fit relative to gabapentin, trazodone, and pregabalin. (pubmed.ncbi.nlm.nih.gov)